Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Objectives Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.Design/setting A prospective, phase 2 clinical tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Howard Streicher, Elad Sharon, Razelle Kurzrock, Young Kwang Chae, Benjamin Tan, Megan Othus, Christine McLeod, Charles Blanke, Helen X Chen, Sandip P Patel, Gabby Lopez, Tridu Huynh, Timothy Kuzel, Christopher W Ryan
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e009074.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849707348930592768
author Howard Streicher
Elad Sharon
Razelle Kurzrock
Young Kwang Chae
Benjamin Tan
Megan Othus
Christine McLeod
Charles Blanke
Helen X Chen
Sandip P Patel
Gabby Lopez
Tridu Huynh
Timothy Kuzel
Christopher W Ryan
author_facet Howard Streicher
Elad Sharon
Razelle Kurzrock
Young Kwang Chae
Benjamin Tan
Megan Othus
Christine McLeod
Charles Blanke
Helen X Chen
Sandip P Patel
Gabby Lopez
Tridu Huynh
Timothy Kuzel
Christopher W Ryan
author_sort Howard Streicher
collection DOAJ
description Objectives Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.Design/setting A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.Participants 21 eligible patients were registered. Median age was 53 years (range 26–69); 16 (76%) were women.Interventions Ipilimumab 1 mg/kg intravenously every 6 weeks with nivolumab 240 mg intravenously every 2 weeks was administered until disease progression, symptomatic deterioration, treatment delay for any reason >56 days, unacceptable or immune-related toxicity with inability to decrease prednisone to <10 mg daily, or per patient request.Main outcome measures The primary endpoint was the overall response rate (ORR) (RECIST V.1.1). Secondary endpoints include clinical benefit rate (CBR) (includes stable disease (SD)>6 months), progression-free survival (PFS), overall survival (OS), and toxicity. Immune-related outcomes included immune ORR (iORR), immune CBR (iCBR), and immune PFS (iPFS). A two-stage design was used assuming: null=5% alternative=30%, n=6 in the first stage, 16 max, one-sided alpha=13%.Results The median number of prior therapy lines was 2 (range: 1–9). 3 of 21 patients attained confirmed partial response (PR) (ORR=14%). In addition, one patient had an unconfirmed PR; one, stable disease (SD)>6 months; one, immune-related RECIST (iRECIST) PR (iPR); and one patient attained iSD>6 months: clinical benefit rate (response or SD>6 months)=5/21 (24%), iORR=4/21 (19%), iCBR=7/21 (33%). The 6-month PFS was 24%; 6-month iPFS, 33%. The PFS for patients (N=7) with iRECIST clinical benefit were 57, 52, 18, 15, 13, 7, and 7 months. The 6-month OS was 76%; the median OS, was 15.8 months. The most common toxicities were fatigue (62%) and rash (38%), and the most common grade 3/4 immune-related adverse events were hepatic dysfunction (9.5%) and adrenal insufficiency (9.5%). Treatment-related adverse events leading to discontinuation of therapy in four patients (21%). There were no grade 5 adverse events.Conclusions Ipilimumab plus nivolumab is active in refractory metastatic adrenocortical cancer meeting the primary endpoint of the study, with a 19% iORR and 33% iCBR (includes SD/iSD>6 months) and with the longest PFS/iPFS of 52 and 57 months.Trial registration number NCT02834013 (registered 15 July, 2016; https://clinicaltrials.gov/ct2/show/NCT02834013).
format Article
id doaj-art-200c10085aef41019eb8269d72020f4d
institution DOAJ
issn 2051-1426
language English
publishDate 2024-07-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-200c10085aef41019eb8269d72020f4d2025-08-20T03:15:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-07-0112710.1136/jitc-2024-009074Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortHoward Streicher0Elad Sharon1Razelle Kurzrock2Young Kwang Chae3Benjamin Tan4Megan Othus5Christine McLeod6Charles Blanke7Helen X Chen8Sandip P Patel9Gabby Lopez10Tridu Huynh11Timothy Kuzel12Christopher W Ryan13Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA5Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA5MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USANorthwestern University, Chicago, Illinois, USAWashington University in St Louis School of Medicine, St Louis, Missouri, USA2Fred Hutchinson Cancer Center, Seattle, WA, USASWOG, San Antonio, Texas, USAOHSU, Portland, Oregon, USACTEP, National Cancer Institute, Bethesda, UK3University of California San Diego Moores Cancer Center, La Jolla, CA, USASWOG Statistical and Data Management Center/Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USAUC San Diego Moores Cancer Center, La Jolla, California, USANorthwestern University Feinberg School of Medicine, Chicago, Illinois, USAOHSU, Portland, Oregon, USAObjectives Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.Design/setting A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.Participants 21 eligible patients were registered. Median age was 53 years (range 26–69); 16 (76%) were women.Interventions Ipilimumab 1 mg/kg intravenously every 6 weeks with nivolumab 240 mg intravenously every 2 weeks was administered until disease progression, symptomatic deterioration, treatment delay for any reason >56 days, unacceptable or immune-related toxicity with inability to decrease prednisone to <10 mg daily, or per patient request.Main outcome measures The primary endpoint was the overall response rate (ORR) (RECIST V.1.1). Secondary endpoints include clinical benefit rate (CBR) (includes stable disease (SD)>6 months), progression-free survival (PFS), overall survival (OS), and toxicity. Immune-related outcomes included immune ORR (iORR), immune CBR (iCBR), and immune PFS (iPFS). A two-stage design was used assuming: null=5% alternative=30%, n=6 in the first stage, 16 max, one-sided alpha=13%.Results The median number of prior therapy lines was 2 (range: 1–9). 3 of 21 patients attained confirmed partial response (PR) (ORR=14%). In addition, one patient had an unconfirmed PR; one, stable disease (SD)>6 months; one, immune-related RECIST (iRECIST) PR (iPR); and one patient attained iSD>6 months: clinical benefit rate (response or SD>6 months)=5/21 (24%), iORR=4/21 (19%), iCBR=7/21 (33%). The 6-month PFS was 24%; 6-month iPFS, 33%. The PFS for patients (N=7) with iRECIST clinical benefit were 57, 52, 18, 15, 13, 7, and 7 months. The 6-month OS was 76%; the median OS, was 15.8 months. The most common toxicities were fatigue (62%) and rash (38%), and the most common grade 3/4 immune-related adverse events were hepatic dysfunction (9.5%) and adrenal insufficiency (9.5%). Treatment-related adverse events leading to discontinuation of therapy in four patients (21%). There were no grade 5 adverse events.Conclusions Ipilimumab plus nivolumab is active in refractory metastatic adrenocortical cancer meeting the primary endpoint of the study, with a 19% iORR and 33% iCBR (includes SD/iSD>6 months) and with the longest PFS/iPFS of 52 and 57 months.Trial registration number NCT02834013 (registered 15 July, 2016; https://clinicaltrials.gov/ct2/show/NCT02834013).https://jitc.bmj.com/content/12/7/e009074.full
spellingShingle Howard Streicher
Elad Sharon
Razelle Kurzrock
Young Kwang Chae
Benjamin Tan
Megan Othus
Christine McLeod
Charles Blanke
Helen X Chen
Sandip P Patel
Gabby Lopez
Tridu Huynh
Timothy Kuzel
Christopher W Ryan
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Journal for ImmunoTherapy of Cancer
title Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
title_full Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
title_fullStr Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
title_full_unstemmed Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
title_short Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
title_sort phase ii basket trial of dual anti ctla 4 and anti pd 1 blockade in rare tumors dart swog s1609 adrenocortical carcinoma cohort
url https://jitc.bmj.com/content/12/7/e009074.full
work_keys_str_mv AT howardstreicher phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT eladsharon phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT razellekurzrock phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT youngkwangchae phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT benjamintan phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT meganothus phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT christinemcleod phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT charlesblanke phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT helenxchen phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT sandipppatel phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT gabbylopez phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT triduhuynh phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT timothykuzel phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort
AT christopherwryan phaseiibaskettrialofdualantictla4andantipd1blockadeinraretumorsdartswogs1609adrenocorticalcarcinomacohort